Nan Fung Life Sciences
James Jin joined Pivotal China as Operating Partner on Aug.2nd, 2021. Prior to joining Pivotal China, James is the Head of Clinical Development in Novartis China from Aug 2019 to Jul 2021. He has about 7-year clinical practice experience in hospital before joining industry. He has more than 18-year working experience and taking leadership role in MNC Medical Dept. He joined Wyeth Pharm in 2003 as Medical Manager and then Boehringer Ingelheim Pharm as Head of Clinical Development & Medical Affairs in 2008. He joined Eli Lilly as Medical Director of Clinical Development & Medical Affairs of Bio-Medicine and then Medical Science Head (i.e., Bio-statistician, programming, HEOR, PV, Medical Writer, Med-information, Patient Education teams) in 2012. He has the rich experience not only in Clinical Development in multi-therapeutic areas (e.g., auto-immunology, CNS, anti-infection, renal disease, respiratory, CV, diabetes, ophthalmology and oncology), but also Clinical Development multi-function teams management and Medical Affairs such as launch readiness. James received his Bachelor of Clinical Medicine in Shanghai Medical University, and then Master& Ph.D. of Urology, Huashan Hospital, Shanghai Medical School, Fudan University in 2003.
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.